Magle Chemoswed Holding (MAGLE) Stock Overview
Engages in research and development of pharmaceutical and medical device products in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MAGLE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Magle Chemoswed Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 11.70 |
| 52 Week High | SEK 35.20 |
| 52 Week Low | SEK 10.50 |
| Beta | 0.12 |
| 1 Month Change | -31.18% |
| 3 Month Change | -38.74% |
| 1 Year Change | -64.55% |
| 3 Year Change | -53.57% |
| 5 Year Change | -72.47% |
| Change since IPO | -42.95% |
Recent News & Updates
Market Cool On Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Revenues Pushing Shares 28% Lower
Jan 27
Health Check: How Prudently Does Magle Chemoswed Holding (STO:MAGLE) Use Debt?
Jan 23Recent updates
Market Cool On Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Revenues Pushing Shares 28% Lower
Jan 27Health Check: How Prudently Does Magle Chemoswed Holding (STO:MAGLE) Use Debt?
Jan 23Sentiment Still Eluding Magle Chemoswed Holding AB (publ) (STO:MAGLE)
Nov 21Investors Give Magle Chemoswed Holding AB (publ) (STO:MAGLE) Shares A 26% Hiding
Aug 12The Magle Chemoswed Holding AB (publ) (STO:MAGLE) Analyst Just Cut Their Revenue Forecast By 10%
Aug 04Here's Why Magle Chemoswed Holding (STO:MAGLE) Has Caught The Eye Of Investors
Feb 28Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Share Price Matching Investor Opinion
Jan 03Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Weaker Than They Seem
Nov 04Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher
Jun 26Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet
Jun 19Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings
Oct 05Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?
Jan 22Shareholder Returns
| MAGLE | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 7.3% | 9.7% | 2.1% |
| 1Y | -64.5% | -7.6% | 6.1% |
Return vs Industry: MAGLE underperformed the Swedish Life Sciences industry which returned -7.6% over the past year.
Return vs Market: MAGLE underperformed the Swedish Market which returned 6.1% over the past year.
Price Volatility
| MAGLE volatility | |
|---|---|
| MAGLE Average Weekly Movement | 8.8% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: MAGLE's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: MAGLE's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 144 | Aaron Wong | www.maglechemoswed.com |
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company’s microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures.
Magle Chemoswed Holding AB (publ) Fundamentals Summary
| MAGLE fundamental statistics | |
|---|---|
| Market cap | SEK 241.60m |
| Earnings (TTM) | -SEK 26.59m |
| Revenue (TTM) | SEK 300.49m |
Is MAGLE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAGLE income statement (TTM) | |
|---|---|
| Revenue | SEK 300.49m |
| Cost of Revenue | SEK 264.00k |
| Gross Profit | SEK 300.22m |
| Other Expenses | SEK 326.82m |
| Earnings | -SEK 26.59m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 27, 2026
| Earnings per share (EPS) | -1.29 |
| Gross Margin | 99.91% |
| Net Profit Margin | -8.85% |
| Debt/Equity Ratio | 59.7% |
How did MAGLE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/08 11:42 |
| End of Day Share Price | 2026/02/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Magle Chemoswed Holding AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |